David P Meeker
CIK 1385155 · President and CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$41.24M
Companies
7
Total Filings
56
Lifetime Open-Market Net
-$7.22M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Director | 20,706 | — | — | $0 | 1 | 2026-06-22 |
| TRVI | Director | 685,012 | $18.37 | $12.58M | $99.1K | 11 | 2026-06-04 |
| RYTM | President and CEO | 270,538 | $105.91 | $28.65M | -$5.01M | 17 | 2026-02-13 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 2,300 | — | — | $0 | 7 | 2020-06-23 |
| SAVIENT PHARMACEUTICALS INC (SVNT) Delisted | Director | 12,644 | — | — | $0 | 1 | 2013-01-17 |
| GENZ | ExecVP,Chief Operating Officer | 0 | $38.25 | $0 | -$2.31M | 8 | 2011-04-06 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | Director | 0 | — | — | $0 | 8 | 2010-09-22 |
Recent Filings · Page 2 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-27 | TRVI | Notice (144) | −4,555 | -$13.6K | EDGAR |
| 2024-06-14 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2024-03-19 | RYTM | Sell (S) | −45,494 | -$1.78M | EDGAR |
| 2024-02-21 | RYTM | Grant (A) | +99,000 | $0 | EDGAR |
| 2024-02-05 | RYTM | Mixed | +9,764 | -$196.5K | EDGAR |
| 2023-06-30 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2023-02-03 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2022-07-01 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2022-06-23 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2022-02-11 | RYTM | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.